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Patients and methods: Bibliographical searches were carried out in PubMed for the terms ‘pulmonary neuroendocrine
tumors’, ‘bronchial neuroendocrine tumors’, ‘bronchial carcinoid tumors’, ‘pulmonary carcinoid’, ‘pulmonary typical/atyp-
ical carcinoid’, and ‘pulmonary carcinoid and diagnosis/treatment/epidemiology/prognosis’. A systematic review of the
relevant literature was carried out, followed by expert review.
Results: PCs are well-differentiated neuroendocrine tumors and include low- and intermediate-grade malignant tumors,
i.e. typical (TC) and atypical carcinoid (AC), respectively. Contrast CT scan is the diagnostic gold standard for PCs, but path-
ology examination is mandatory for their correct classiﬁcation. Somatostatin receptor imaging may visualize nearly 80% of the
primary tumors and is most sensitive for metastatic disease. Plasma chromogranin A can be increased in PCs. Surgery is the
treatment of choice for PCs with the aim of removing the tumor and preserving as much lung tissue as possible. Resection of
metastases should be considered whenever possible with curative intent. Somatostatin analogs are the ﬁrst-line treatment of
carcinoid syndrome and may be considered as ﬁrst-line systemic antiproliferative treatment in unresectable PCs, particularly
of low-grade TC and AC. Locoregional or radiotargeted therapies should be considered for metastatic disease. Systemic
chemotherapy is used for progressive PCs, although cytotoxic regimens have demonstrated limited effects with etoposide
and platinum combination the most commonly used, however, temozolomide has shown most clinical beneﬁt.
Conclusions: PCs are complex tumors which require a multidisciplinary approach and long-term follow-up.
Key words: pulmonary, carcinoid, bronchial, typical carcinoid, atypical carcinoid, neuroendocrine tumor
introduction
This expert consensus document represents an initiative by the
European Neuroendocrine Tumor Society (ENETS) to provide
guidance on the management of pulmonary carcinoid (PC)/
well-differentiated neuroendocrine tumors (NETs) taking into
account advances in the characterization of NETs as well as
improvements in both diagnosis and treatment. This ‘expert’
consensus opinion arises from two meetings of the ENETS
Advisory Board held in 2012 and 2013. There is a paucity of
randomized studies and as the disease is relatively uncommon
the level of evidence is limited compared with more common
cancers. All agree that the management of such patients should
involve a multidisciplinary tumor board with a speciﬁc interest/
expertise in NETs. The terminology used reﬂects the current
practice of the term ‘carcinoid’ in pulmonary disease, speciﬁcal-
ly typical (TC) and atypical (AC) carcinoids. At this stage, there
has not been a move to change toward the WHO terminology
for gastroenteropancreatic (GEP) NETs. A systematic review of
the relevant literature was carried out, and this was followed by
appraisal and expert review.
literature search methods
The Oxford Centre for Evidence-Based Medicine’s Levels of
Evidence (2011; Centre for Evidence-Based Medicine, Levels of
Evidence, http://www.cebm.net/index.aspx?o¼1025) were used to
evaluate the evidence cited in this consensus document, and out-
comes were additionally graded according to the modiﬁed Grading
of Recommendations Assessment Development and Evaluation
Working Group 2007 (http://www.gradeworkinggroup.org/).
Bibliographical searches were carried out in PubMed for the
terms ‘pulmonary neuroendocrine tumors’, ‘bronchial neuroen-
docrine tumors’, ‘bronchial carcinoid tumors’, ‘pulmonary car-
cinoid’, ‘pulmonary typical carcinoid’, ‘pulmonary atypical
carcinoid’, ‘pulmonary carcinoid and diagnosis’, ‘pulmonary
carcinoid and treatment’, ‘pulmonary carcinoid and epidemi-
ology’, and ‘pulmonary carcinoid and prognosis’. For each term,
the search was carried out without any ﬁlter in ﬁrst instance,
thereafter applying ﬁlters for publication type [Randomized,
controlled trials (RCTs), Case Reports] and using the Mesh
Terms ‘Case-control Studies’ and ‘cohort studies’. No language
restriction was applied.
literature search results
For the term ‘pulmonary neuroendocrine tumors’, we found
11 302 articles in total, 2669 case reports, 1028 cohort studies,
580 case-control studies, and 36 RCTs. For the term ‘bronchial
neuroendocrine tumors’, we found 1834 articles in total, 761
case reports, 233 cohort studies, and 124 case-control studies,
while no RCT was available. For the term ‘bronchial carcinoid
tumors’, we found 1611 articles in total, 661 case reports, 224
cohort studies, and 119 case-control studies, while no RCT was
available. For the term ‘pulmonary carcinoid’, we found 3080
articles in total, 1027 case reports, 454 cohort studies, 274 case-
control studies, and 5 RCTs. For the term ‘pulmonary typical
carcinoid’, we found 575 articles in total, 135 case reports, 131
cohort studies, 85 case-control studies, and 1 RCT. For the term
‘pulmonary atypical carcinoid’, we found 576 articles in total,
137 case reports, 123 cohort studies, and 87 case-control studies,
while no RCT was available. For the terms ‘pulmonary carcinoid
and diagnosis’, we found 2554 articles in total, 895 case reports,
421 cohort studies, 257 case-control studies, and 4 RCTs. For
the terms ‘pulmonary carcinoid and treatment’, we found 1420
articles in total, 539 case reports, 331 cohort studies, 185 case-
control studies, and 3 RCTs. For the terms ‘pulmonary carcinoid
and epidemiology’, we found 339 articles in total, 17 case re-
ports, 158 cohort studies, 109 case-control studies, and 1 RCT.
Finally, for the terms ‘pulmonary carcinoid and prognosis’, we
found 192 articles in total, 7 case reports, 96 cohort studies, and
70 case-control studies, while no RCT was available.
We excluded in vitro and animal studies, and prioritized
meta-analyses, systematic reviews, and RCTs where available.
We ﬁnally identiﬁed a total of 176 pertinent articles with the
strongest level of evidence. In more detail, we considered 54
articles for ‘Epidemiology paragraph’, 36 for ‘Pathology
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paragraph’, 35 for ‘Diagnosis paragraph’, 15 for ‘Surgery para-
graph’, and 36 110 for ‘Medical therapy paragraph’.
terminology issue
The term neuroendocrine (NE) neoplasm encompasses the
whole spectrum of lung tumors characterized by NE morph-
ology and differentiation [1, 2], including well-differentiated and
poorly differentiated tumors. The historical term carcinoid,
either TC or AC for the subgroups of well-differentiated NET, is
preferable over other proposed alternative names derived from
the concept of either tumor grading [3–5], tumor extension
(localized versus metastatic) [6] or tumor behavior [7, 8]. This is
because TC and AC are identiﬁed as unique clinico-pathological
traits that separate it clearly from the remaining (poorly differ-
entiated) NET which includes the high-grade large cell neuroen-
docrine carcinoma (LCNEC) and small cell lung carcinoma
(SCLC) [2]. In the following text, the terms PC and pulmonary
NET will be used.
epidemiology
PCs are rare tumors with an age-adjusted incidence rate ranging
from 0.2 to 2/100 000 population/year in both US and European
countries [9–23]. There has been an increasing prevalence over
the last 30 years, 6% per year, regardless of confounding
demographic factors, such as age, gender, race, and stage distri-
bution [16, 24]. This tendency of PCs to increase over time is
likely due to improved awareness [25, 26] and increased use of
special immunohistochemistry (IHC) stains [14, 16, 21, 27].
PCs prevail slightly in women over men, in whites over blacks,
or other ethnicities including Hispanic and Asian people [10–
14, 16, 18–23, 28–31]. They occur in the fourth to sixth decades
of life, with a younger mean age (45 years) for TC and one
decade later for AC [20, 30–33]. PCs are the most common
primary lung neoplasm in children [34, 35] and late adolescents
[35–38], with TC prevailing by far over AC.
The prevalence of pulmonary NETs compared with the main
subtypes of lung cancer has remained relatively unchanged
except for SCLC, which has shown decreasing incidence, at least
in men [10], probably due to major changes in smoking habits
[27]. Currently, PCs account for 1–2% of all invasive lung
malignancies, roughly corresponding to one-fourth to one-third
of all well-differentiated NETs throughout the body. The large
majority of poorly differentiated NE carcinomas (NECs),
accounting for 90%, develop in the lung [16, 17, 20, 39, 40]
likely due to their strong association with smoking.
The majority of PC patients develop in never or current light
smokers [31, 41–45], although more AC patients are current or
former smokers than TC patients [11, 30, 41, 44]. In contrast,
SCLC and LCNEC are associated with heavy smokers [2]. PCs
may also develop in patients with a previous history of cancer
(especially skin, urogenital, and respiratory tract) [30], although
the frequency of these tumors in the population may account
for this association and PC may be detected due to increased
surveillance. PCs are usually sporadic lesions; however, rare fa-
milial cases have been reported [46, 47]. Up to 5% of patients
with multiple endocrine neoplasia type 1 (MEN1) harbor PCs,
usually TC with a smaller number of AC [22, 48–51]. Clinical
evolution of these familial tumors is generally favorable, but life-
threatening tumors are also on record [46].
The ratio between TC and AC is about 8–10 : 1, so AC is the
most uncommon of the lung NETs [2, 27–29, 52], even though
some recent studies have described a relative excess of AC diag-
noses [17, 20, 30]. Due to inconsistency in AC reporting or
coding, data from cancer registries are not generally reliable for
information about TC versus AC including data from the
National Cancer Institute (NCI) Surveillance, Epidemiology,
and End Results (SEER) program because peer review of the
histological slides is not possible [53].
The decreased survival of PCs observed over the last 30 years
is likely due to an increased recognition of AC over TC [27].
This distribution is closely in keeping with the current histo-
logical classiﬁcation, as TCs are metastatic in up to 15% of cases,
usually to regional lymph nodes, with a median time to recur-
rence of 4 years, whereas ACs are regionally or distantly meta-
static in up to one half of tumors with a median time to
recurrence of 1.8 years. However, for both TC and AC, recur-
rence may not occur until many years later, hence the need for
long-term surveillance [2, 18, 21, 54].
PCs are also detected in lung cancer screening low-dose com-
puted tomography (CT) trials, especially at the baseline with a
prevalence of TC over AC [25, 26]. On annual repeat controls,
AC tends to prevail probably because of its inherent greater ma-
lignant potential [25].
pathology
classiﬁcation
PCs are classiﬁed according to the widely agreed WHO 2004
scheme [2], i.e. TC and AC. The term of carcinoid has been
maintained during all WHO classiﬁcations published since
1967, even though the diagnostic criteria separating TC from
AC were only introduced in the 1999 WHO classiﬁcation and
subsequently maintained in the 2004 WHO classiﬁcation [2,
55]. Many other classiﬁcation schemes and terminologies have
been proposed over time, either introducing a concept of tumor
grading [3–5, 56], applying different thresholds to current diag-
nostic criteria [7, 57], or generalizing the taxonomy used in
GEP NETs [6, 58, 59]. These different proposals have not gained
general acceptance yet because of the lack of clear clinical evi-
dence for signiﬁcant advantages over the current WHO classiﬁ-
cation. The recent proposal of tumor grading based on a
combination of KI-67 labeling index, mitotic rate, and necrosis
may be of clinical importance if it can be validated [56].
PCs are tumors with NE morphology and differentiation,
which are deemed to derive from, or differentiate toward, the
mature NE cells of the pulmonary diffuse NE system [60–62].
They encompass low (TC) to intermediate (AC) malignant
lesions, which do not have any causative relationship or
common genetic/epidemiologic/clinic traits with SCLC and
LCNEC [2, 63]. In particular, PCs as a whole are well-differen-
tiated tumors as opposed to SCLC and LCNEC, with TC
sharing some homologies with Grade 1 NETs and AC some
homologies with Grade 2 NETs of the GEP tract. SCLC and
LCNEC widely correspond to the Grade 3 NEC category of the
GEP tract [2, 64].
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TC has fewer than 2 mitoses/2 mm2 and absence of necrosis,
and AC has 2–10 mitoses/2 mm2 and/or foci of punctate necro-
sis. SCLC and LCNEC have more than 10 mitoses/2 mm2
(usually greater than 50/2 mm2) and extensive geographic ne-
crosis [2, 55, 65]. A mitotic count should be carried out in
hotspot areas. A report that IHC methods may be useful to
highlight mitotic ﬁgures needs further conﬁrmation [66].
Diagnostic criteria regarding the assessment of cell features (di-
mension of tumor cells, prominence of nucleoli, and chromatin
pattern) are used to better classify poorly differentiated NECs
(SCLC and LCNEC), whereas they do not serve to distinguish
TC and AC. Molecular studies have shown differences between
TC and AC and high-grade NECs [67]. There are limitations
regarding reproducibility in differences of counting mitosis/
area. Since the difference of one mitoses (e.g. from 10 to 11)
makes an arbitrary difference in diagnostic category from AC to
LCNEC, further studies are mandatory.
Combined tumors have been described for both SCLC and
LCNEC [2], whereas the association of PC with conventional
NSCLC is extremely rare.
grading system
Grading of NE lung tumors is inherently present in the current
classiﬁcation scheme [2]. Considerable clinical and epidemiologic
data exist to validate this grading system resulting in a pathologic
four-tier and clinical three-tier spectrum of NE-differentiated
tumors characterized by aggressiveness: TCs are low-grade ma-
lignant; AC intermediate-grade malignant; and LCNEC and
SCLC are high-grade malignant NETs [2–5]. SCLC is so com-
mon to the lung to make it a distinctive entity with its own epi-
demiologic, genetic, clinical, and pathologic traits. However,
establishing a grading system in lung NETs independent of hist-
ology could be clinically useful, although the criteria for grading
lung NET may be different from those used for GEP NETs [68].
Such a grading system could include Ki-67, mitotic rate, and ne-
crosis as recently proposed; however, there is a signiﬁcant need
for further validation studies [56].
Ki-67 immunoreactivity
Ki-67 antigen IHC (the product of MKI67 gene mapping to
10q26.2 gene involved in cell proliferation), which is generally
carried out by using the clone Mib-1 and mostly expressed as la-
beling index (percentage of positive tumor cells or labeling
index), has a value in distinguishing PCs from high-grade NETs
in small crushed biopsies [69]. However, Ki-67 expression does
not reliably separate TC from AC, much less SCLC from
LCNEC, better than the existing 2004 WHO histological criteria
[2]. Ki-67 may play a role in predicting prognosis on resected
specimens of PCs; however more data are needed to determine
the utility in lung NETs [56, 68, 70–72] as opposed to GEP
NETs where Ki-67 labeling index is an integral part of the
current grading system [1, 73–75]. Consensus regarding the
optimal methods to adopt for assessing Ki-67 labeling index
(digital image analysis, manual counting, eyeball estimation,
and number of cells) is still lacking [75], even though some
studies pointed to consider manual counting of at least 2000
cells in hotspot histological ﬁelds [52, 71, 72, 76, 77]. A high
overall agreement of manual Ki-67 labeling index evaluation
and an automated assessment method upon scanned slides have
recently substantiated the value, reproducibility, and ease of Ki-
67 labeling index upon manual mitotic counting [56, 78].
tumor staging
Tumor staging of PCs is recommended according to the Union
Internationale Contre le Cancer/American Joint Committee on
Cancer (UICC/AJCC) 7th ed. TNM system [53, 73], although it
will be necessary to reﬁne descriptive categories according to
tumor size, multicentricity, or other components of T, N, and M
factors to be meaningful also in PCs [International Association
for the Study of Lung Cancer (IASLC) Lung Cancer Perspective
Staging Project]. Resection margins should be indicated, meas-
uring the distance from the tumor edge to guarantee radical ex-
cision on surgical specimens [79]. Long-term studies, however,
are needed to assess the risk and rate of relapse for R1 resection.
Most cases of multiple carcinoids are synchronous primaries
rather than intrapulmonary metastases, particularly in the
setting of Diffuse IdioPathic NeuroEndocrine Cell Hyperplasia
(DIPNECH) [53].
other pathology information
The occurrence of NE cell hyperplasia in the surrounding lung
tissue should be accurately documented [2]. This may require
representative sampling of the non-neoplastic lung surrounding
resected carcinoid tumors. Most cases of NE hyperplasia re-
present an incidental ﬁnding in the non-neoplastic lung tissue
adjacent to 25% of excised carcinoid tumors [80]. It is deﬁned
by the growth of NE cells proliferating in single cells and clusters
within the bronchial epithelium. Nodular NE cell proliferations
measuring <0.5 cm are termed ‘tumorlets’ and they typically
show no mitoses, no necrosis, and a low Ki-67 labeling index
[2], but may be detected on CT scan as subcentimeter multiple
lung nodules. Incidental NE cell hyperplasia is relatively
common, but DIPNECH is extremely rare and is characterized
by widespread NE cell hyperplasia and tumorlets. It is regarded
as a pre-invasive lesion associated with some risk of developing
TC or AC, which can be multiple [51, 81–84]. In DIPNECH, a
high-resolution CT scan with an expiration study may show not
only multiple nodules due to the tumorlets and carcinoid
tumors, but it may show ground glass attenuation, bronchiec-
tasis, and air trapping due to small airway obstruction [85].
IHC demonstration of few selected markers [chromogranin
A, synaptophysin and/or CD56, cytokeratins, and thyroid tran-
scription factor-1 (TTF1)] may help to conﬁrm NE and epithe-
lial differentiation, especially in limited diagnostic material [2].
These immunostains do not distinguish TC from AC, even
though the latter may present with more irregular distribution
of NE markers. TTF1 is more commonly found in peripheral
PC and cytokeratins may assist in the diagnostic recognition of
pulmonary paraganglioma [2]. The separation of PC from poorly
differentiated NET, especially in limited diagnostic material, may
be reliably made exploiting Ki-67 labeling index [68]. Immunos-
tains for CDX-2, Islet1, TTF1 or speciﬁc hormones, and biogenic
amines might be used to separate pulmonary NET from lung me-
tastases of well-differentiated NET of other organs usually GEP in
origin [86, 87]. Breast or prostate cancer may exhibit NE differen-
tiation, which may lead to diagnostic confusion with PC, when
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they are metastatic to the lung but can be reliably diagnosed by
additional immunohistochemical assessment [88, 89]. Histologic-
al variants of PCs (spindle cell, oncocytic, and melanocytic) may
impact on differential diagnosis, but do not have clinical rele-
vance. No molecular tests should currently be routinely carried
out in PC samples. If clinically needed, somatostatin receptors
(SSTRs) can be examined [90].
small biopsy and/or cytology samples
A correct diagnosis in small biopsies and/or cytology samples
requires careful attention to morphologic and IHC features. TC
and AC cannot be distinguished in biopsy and cytology, whereas
AC may be suspected if mitoses or necrosis are present. If a low
proliferation activity is seen by Ki-67 labeling index, this may be
helpful to exclude high-grade NECs even in small biopsy speci-
mens [69]. Likewise, Ki-67 antigen IHC can effectively be used
in cytology preparations to avoid misdiagnosis of poorly differ-
entiated NET [69], whereas this procedure is not reliable for dis-
tinguishing TC from AC on conventional smears. Immunostains
for pan-endocrine markers to conﬁrm the NE nature of tumor
cells are useful in limited diagnostic material, whether biopsy or
cytology. Cytokeratins (pool AE1/AE3) may be negative in up
to 25% of PCs, but are consistently positive in SCLC and
LCNEC.
pathology recommendations for the best
practice
• Pathology is the gold standard in the assessment of any pul-
monary NET diagnosis. Problem cases may beneﬁt from
review by expert pathologists (Level of Evidence 3; Grade of
recommendation B).
• Current standard for classiﬁcation and nomenclature is the
2004 WHO classiﬁcation. Relevant information also derives
from the UICC/AJCC 7th edition TNM staging. Other classi-
ﬁcations are not recommended (Level of Evidence 3; Grade of
recommendation B).
• Pathology report on pulmonary NETs should be shared by
the multidisciplinary team along with oncologists, radiolo-
gists, nuclear medicine physicians, surgeons, pneumologists,
and endocrinologists, where pathologists contribute to the
clinical decision-making process (Level of Evidence 5; Grade
of recommendation C).
• PCs as a whole are well-differentiated NETs as opposed to
poorly differentiated SCLC and LCNEC, and include low-
grade malignant tumors, i.e. TC, and intermediate-grade ma-
lignant tumors, i.e. AC. TC is closest to the G1 GEP NETs and
AC is closest to the G2 GEP NETs. SCLC and LCNEC gener-
ally correspond to the NEC category of the gastrointestinal
tract according to the current WHO classiﬁcation. Diagnostic
criteria, however, still rely primarily on histology (Level of
Evidence 3; Grade of recommendation B).
• Separation of TC from AC requires a surgical specimen. TC
and AC cannot be reliably distinguished from each other
in small biopsy and cytology (Level of Evidence 3; Grade of
recommendation C).
• Mitotic count, necrosis, and Ki-67 labeling index should be
indicated in the pathology reports of surgical specimens or
biopsy samples for at least two reasons: (i) mitoses and necro-
sis are part of the classiﬁcation criteria and permit cross-study
comparisons; (ii) since the mitotic rate and Ki-67 proliferation
index impact on survival even within AC (Level of Evidence 3;
Grade of recommendation C).
• There are at least four major issues regarding Ki-67 labeling
index assessment in NE lung tumors: (i) Ki-67 is useful in
biopsy for distinguishing TC and AC from SCLC cytology
(Level of Evidence 4; Grade of recommendation C); (ii) Ki-67
does not reliably distinguish TC from AC in any material
(Level of Evidence 4; Grade of recommendation C); (iii) Ki-67
has been shown to predict prognosis of TC and AC (Level of
Evidence 4; Grade of recommendation C); and (iv) the optimal
procedure for performing Ki-67 ICH and the criteria for per-
forming the relevant labeling index (digital image analysis,
manual counting, eyeball evaluation, hotspot areas versus ran-
domly selected ﬁeld versus entire tumor area, and number
of cells) remains to be settled (Level of Evidence 4/5; Grade of
recommendation C).
• A few NE immunomarkers (chromogranin A, synaptophysin,
and/or CD56/NCAM) may be used to conﬁrm NE nature of
tumors especially in biopsy/cytology specimens or surgical
specimens, if needed. In case of metastatic PC presentation,
positive TTF1 staining is suggestive of a lung or thyroid origin
(Level of Evidence 3; Grade of recommendation C).
• NE cell hyperplasia, tumorlets, DIPNECH, and multiple
tumors should be carefully documented and most often
pertain to PCs. DIPNECH is a pre-invasive lesion able to pro-
gress to TC or AC. Histological evaluation may provide infor-
mation to decide if multiple PCs are intrapulmonary seeding
or multiple primaries, as an association with NE cell hyper-
plasia, tumorlets, or DIPNECH favors multiple NETs (Level
of Evidence 4; Grade of recommendation C).
• No proof has been provided that different histological tumor
cell features may have clinical signiﬁcance, although they may
seriously impact differential diagnosis. Cell atypia or pleo-
morphism is not useful to classify PCs (Level of Evidence 4;
Grade of recommendation C).
• No molecular tests should currently be routinely carried out
in PCs, unless speciﬁcally required by study protocols (Level
of Evidence 4; Grade of recommendation C).
diagnosis
PCs are traditionally subdivided into central and peripheral on
the basis of their origin in respect of the bronchial tree; however,
they can occur throughout the lung parenchyma. Respiratory
symptoms are generally present only in central forms, while per-
ipheral forms are generally discovered as an incidental ﬁnding
in the course of radiological procedure carried out for other
reasons. The most frequent respiratory symptoms are recurrent
chest infections, cough, hemoptysis, chest pain, dyspnea, and
wheezing. In rare cases, hormonal hypersecretion reveals the
underlying tumor.
There are some difﬁculties in the generation of recommenda-
tions for imaging and surgery for PC because many patients
present with a ‘lung mass’ rather than a preoperative diagnosis
of a PC; thus, preoperative workup and imaging needs to be
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pragmatic and shown to add value to justify any additional cost
and delay to deﬁnitive surgical treatment.
Needless to say all patients should be discussed within a
multidisciplinary tumor board with a specialist interest in PCs
to establish the most appropriate management for patients
(Figures 1 and 2).
biochemical assessment
The baseline tests should be limited to renal function, calcium,
glucose, and plasma chromogranin A measurements [91–93]. In
syndromic patients, speciﬁc markers are measured, e.g. 24-h
urine 5-hydroxyindoleacetic acid measurement in carcinoid
syndrome [94–96]. Carcinoid syndrome is found in 2–5% of
PCs, most often when liver metastases are present. Cushing’s
syndrome is found in 1–6% of patients and measurements
recommended include serum cortisol, 24 h urine free cortisol,
and adrenocorticotropic hormone (ACTH). Up to 40% of
patients presenting with ectopic Cushings are found to have a
PC. Acromegaly due to ectopic growth hormone-releasing
hormone (GHRH) or insulin-like growth factor 1 (IGF-1) is a
rare association and serum growth hormone; GHRH and IGF-1
can be measured when clinically indicated. Extremely rarely
ectopic insulin secretion may be associated in patients present-
ing with recurrent hypoglycemic episodes. The syndrome of in-
appropriate antidiuretic hormone secretion is found in 5% of
patients with SCLC and rarely in PC [94, 96, 97].
MEN1-associated forms
PC may be rarely associated with MEN1 syndrome (<5% of
patients) and should not be confused with a metastatic spread
or a second cancer. MEN1 is investigated by family history, clin-
ical examination, and minimal laboratory screening including
ionized calcium, intact parathyroid hormone, and prolactin
[98]. If the familial history is suggestive of a MEN1 syndrome or
a second MEN1 feature is present, e.g. hyperparathyroidism,
screening for MEN1 mutational analysis should be carried out
[96, 99].
radiological imaging at diagnosis
More than 40% of the cases may be incidentally detectable on a
standard chest X-ray [100]. The gold standard is a contrast CT
scan. A standard lung CT acquisition technique is used. A delay of
20 s between the injection of contrast and images acquisition is
required to obtain a good contrast enhancement of mediastinal
structures. In patients in whom contrast is contraindicated, high-
resolution CT may be used [81, 94, 95, 101, 102].
The CT imaging features of a PC is often nonspeciﬁc and may
have similar appearances to adenocarcinoma or an epidermoid
lung carcinoma. The most common appearance is a round or
ovoid shape peripheral lung nodule with smooth or lobular
margins [101]. PCs, however, are often highly vascular and typ-
ically enhance following intravenous contrast administration
[102]. They tend to grow very slowly when compared with other
types of lung cancer.
In central forms, PCs are most often associated with indirect
signs of obstruction on CT such as atelectasis, air trapping, ob-
structive pneumonitis or rarely, bronchiectasis or lung abscess.
For DIPNECH, high-resolution CT with an expiration study
is useful as it shows mosaic attenuation or air trapping in
Clinical suspicion of pulmonary
neuroendocrine tumor
(Typical or Atypical Carcinoid)
Evaluate possible MEN1 association
(include: ionized serum calcium, PTH,
consider MEN1 gene mutational analysis)
Assessment of biochemical secretion
depending on clinical signs and history:
24h urine 5HIAA
serum cortisol and ACTH
GHRH, IGF1
If considering surgery perform:
Echocardiography
Respiratory Function testing
Histopathology: Evaluation of Mitotic
count and/or necrosis, include Ki67
proliferation index.
Cytopathology: may not differentiate TC
from AC
Multiphasic contrast CT chest
& abdomen
Bronchoschopy
(EBUS in selected cases)
Transthoracic and/or
transbronchial biopsy.
Metastatic disease: biopsy
most accessible site
Spine MRI if symproms
or suspicion of
metastases
If positive cytology or
histopathology:
OctreoScanTM or Ga68-
DOTA-Octreotate PET.
Consider FDG-PET in AC or
high grade histopathology
Figure 1. Algorithm for diagnosis of pulmonary neuroendocrine tumor.
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addition to multiple nodules due to the tumorlets and carcinoid
tumors.
TNM staging
Patients should be staged according to the UICC 7th TNM clas-
siﬁcation. Both conventional and scintigraphic imaging are used
to stage PC patients. N2 staging does not represent an absolute
contraindication for surgery due to the indolent course of a sig-
niﬁcant number of patients.
Controversy exists on the optimum mode of preoperative
staging in the mediastinum. This is because of the lack of infor-
mation and consensus on surgery for patients with mediastinal
lymph node involvement, for example, in a recent survey by the
European Society of Thoracic Surgeons, many surgeons across
Europe would offer upfront surgery for patients with clinical N2
disease as long as the primary tumor was deemed to be resect-
able [32]. If that is the case, then it could be argued that no
further invasive staging is required if initial nuclear imaging
suggests N2 disease. However, there are few studies which have
analyzed in depth the reasons for the impact of the presence of
lymph node involvement in the prognosis of PCs. In the
EMETNE’s experience, most patients with TC who presented
metastasis or local recurrence in follow-up were in stage I and
more than 55% are alive after treatment. Among the AC cases
with this evolution, however, 66% had lymph node metastases,
and 80% of them died after treatment because of the recurrence.
The analysis of these results enables us to conﬁrm that nodal in-
vasion demonstrates an obvious inﬂuence in the prognosis of
AC [103].
Imaging is also crucial for determining distant metastases.
The most common sites of PC metastases are the liver, bones,
and mediastinal lymph nodes [104]. Multiphase CT including
arterial and portal phase or magnetic resonance imaging (MRI)
with dynamic acquisition and diffusion-weighted sequences of
the liver should be used for the detection of liver metastases
[105].
CT with appropriate window setting may be useful to reveal
bone metastases; however, MRI is the technique of choice for
detection and characterization of bone metastases, especially of
the spine. Somatostatin receptor scintigraphy (SRS) and most
recently SSTR positron emission tomography (PET) imaging
may have a higher grade of sensitivity for bone metastases [106,
107] (see below).
nuclear medicine techniques
Nuclear medicine techniques may play a role in the diagnosis
since they are more speciﬁc than conventional imaging for TC
and ‘lower grade’ AC and enable whole-body imaging for
staging, and help to predict the response to peptide receptor
radiotargeted therapy (PRRT).
Whole-body SRS with thorax single-photon emission CT
(SPECT)/CT may be useful to determine the N and M stage at
diagnosis in the preoperative phase. Nearly 80% of the primary
tumors, predominantly TC, may be visualized with this tech-
nique [79, 94, 106, 108]. The SUV at ﬂudeoxyglucose (FDG)
PET is generally higher in AC with a higher proliferation index,
thus demonstrating that FDG PET is helpful in determining the
biology of PC [109]. FDG PET is the most sensitive technique
for poorly differentiated forms (SCLC and LCLC) [110, 111].
Hormone-Related
Symptoms
Lung carcinoid
Control of hormone
related symptoms:
see Fig 2a
Atypical Carcinoid or
actively progressive*
Typical Carcinoid
Residual tumor
or slowly
progressive*
*Progression is defined
according to RECIST criteria
PRRT: peptide radiolabeled receptor
radiotherapy
Somatostatin
Analogues
Bilateral
Adrenalectomy
•  Locoregional
   therapy
•  Interferon
•  PRRT
•  Somatostatin
   Analogues
•  Interferon
•  Everolimus (within
   study)
•  Chemotherapy
   (e.g.Temozolomide)
•  PRRT
•  Surgery if feasible
•  Observation
•  Somatostatin Analogues
•  Image-guided local therapy
•  As per AC for active
   progressive disease
Control of cortisol
secretion e.g.
Metapyrome
Carcinoid Syndrome Cushings Syndrome
A B
Figure 2. (A) ENETS recommendations for the control of hormone-related symptoms. (B) ENETS recommendations for the control of hormone-related
symptoms and tumor growth. *Progression is deﬁned according to RECIST criteria. PRRYT: peptide radiolabeled receptor radiotherapy.
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A study by Pattenden et al. [112] reported the sensitivity and
speciﬁcity of 18F-FDG PET/CT for the diagnosis of mediastinal
lymph node disease in 207 patients with TC and AC as 33 and
94%, respectively, suggesting that lymph node metastases
cannot accurately be ruled out with a negative PET–CT in TC. If
treatment decisions are based on the N2 status, further medias-
tinal staging using either endobronchial ultrasound/endoscopy
ultrasound ﬁne needle aspiration or mediastinoscopy and
lymph node biopsies will be required.
Whenever available, Gallium-68-1,4,7,10-tetraazacyclodo-
decane-1,4,7,10-tetraacetic acid (DOTA) somatostatin analog
[SSA; either octreotate, octreotide, or Nal(3)-octreotide] PET
is more sensitive and preferable to SRS [95, 107, 113–116].
C11-5-hydroxytryptophan PET and 64Cu DOTATATE are
promising techniques for lung NET, but experience is limited
to single centers [117, 118].
other diagnostic techniques
Other techniques are required to reach the deﬁnitive diagnosis
and to perform the WHO classiﬁcation and staging. These
include:
bronchoscopy
Bronchoscopy is indicated in all the central forms. It also
enables biopsy. Flexible bronchoscopy is preferable; however,
the clinician should be aware of the possibility of bleeding.
In patients at high risk for bleeding, rigid bronchoscopy may
be preferred, both for obtaining biopsy specimens and also for
performing ablation procedures [94, 96, 119].
There is currently limited evidence regarding the added value
of new bronchoscopic techniques (echo-endoscopy, ﬂuores-
cence bronchoscopy, and microbronchoscopy) to increase the
sensitivity of detection of primary tumors, recurrence, or medi-
astinum lymph node staging and to determine endobronchial
tumor margins before surgical resection [120, 121].
For peripheral lesions, biopsy specimen may be obtained by
either endoscopic transbronchial biopsy or more frequently a
transthoracic CT-guided biopsy. It should be emphasized that
the small biopsies may make it difﬁcult to differentiate between
TC and AC [69, 94, 96, 119, 120].
functional respiratory tests
Functional respiratory tests should always be carried out to
assess the surgical risk and to screen for bronchostenosis and to
assess for the not infrequent association with chronic obstruct-
ive airways disease [122].
echocardiography
Echocardiography should be carried out at diagnosis and in the
course of follow-up to evaluate the presence and evolution of
carcinoid heart disease [123]. In PC, left- as well as right-side
valves should be screened [123, 124]. Accurate echocardio-
graphic evaluation should always be carried out before surgical
procedures.
It should be remembered that the carcinoid syndrome may be
diagnosed in pulmonary NET even in the absence of liver me-
tastases and therefore carcinoid heart disease may be present,
particularly on the left side. Furthermore, the association with
AC syndrome with bronchospasm may additionally impact on
the heart function.
cerebral CT or MRI
Cerebral metastases are a common event in poorly differentiated
NETs, but are anecdotal in PC more often with higher grade
AC. Cerebral CT or MR is not routinely recommended, but
should be carried out in the staging phase and during the
follow-up when there is clinical suspicion or indication of
disease. For the same reasons, prophylactic cerebral radiother-
apy, which is recommended in small cell carcinoma, is not justi-
ﬁed in these tumors.
diagnosis: recommendations for the best
practice
• Biochemical baseline tests should be limited to renal function,
liver function, calcium, glucose, and plasma chromogranin A
measurements (Level of Evidence 4, Grade of recommendation D).
• Paraneoplastic syndrome might occur in the setting of PC.
Biochemical testing should be carried out in consideration of
clinical symptoms and features including as appropriate 24-h
urine 5-hydroxy-indole-acetic acid, ACTH, and GHRH (Level
of Evidence 4, Grade of recommendation A).
• PC may be associated with MEN1 syndrome in <5% of pa-
tients. MEN1 is investigated by family history, clinical exam-
ination, and minimal laboratory screening (Level of Evidence
4, Grade of recommendation C). If the familial history is sug-
gestive of a MEN1 syndrome or a second MEN1 feature is
present, screening for MEN1 gene mutation should be carried
out (Level of Evidence 5, Grade of recommendation C).
• More than 40% of the cases may be incidentally detectable on
a standard chest X-ray (Level of Evidence 3/4, Grade of recom-
mendation C).
• The gold standard is contrast CT (Level of Evidence 3, Grade
of recommendation B). In patients in whom contrast is contra-
indicated, high-resolution CT may be used (Level of Evidence
4, Grade of recommendation C).
• Multiphase CT including arterial and portal phase or MRI
with dynamic acquisition and diffusion-weighted sequences
of the liver should be used for the detection of liver metastases
(Level of Evidence 4, Grade of recommendation C).
• A CT chest and abdomen should be undertaken for preopera-
tive staging (Level of Evidence 4, Grade of recommendation A,
strong recommendation for good practice).
• Bronchoscopy may be required for the staging and assessment
of central airway tumors preoperatively (Level of Evidence 4,
Grade of recommendation A).
• Flexible bronchoscopy is preferable; however, in patients at
high risk for bleeding, rigid bronchoscopy may be preferred
for obtaining biopsy specimens (Level of Evidence 4, Grade of
recommendation B).
• There is currently limited evidence regarding the added value
of new bronchoscopic techniques to increase the sensitivity of
detection of primary tumors or recurrence (Level of Evidence
4, Grade of recommendation D).
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• Small biopsies may make it difﬁcult to differentiate between
TC and AC (Level of Evidence 4, Grade of recommendation C).
• Whole-body SRS with thorax SPECT/CT may be useful to
visualize nearly 80% of the primary tumors (Level of Evidence
4, Grade of recommendation B).
• SRS and SSTR PET imaging may have a higher grade of sensi-
tivity for bone metastases (Level of evidence 4, Grade of recom-
mendation D).
• Gallium-68-DOTA SSA PET is more sensitive and preferable
to SRS if available (Level of Evidence 4, Grade of recommenda-
tion C).
• Most TCs have low or no uptake on FDG PET, whereas ACs
may have higher uptake. FDG PET is most useful for poorly
differentiated forms (SCLC and LCLC) (Level of Evidence 4,
Grade of recommendation C).
• Functional respiratory tests should always be carried out to
assess the surgical risk and the association with chronic ob-
structive airways disease and to screen for bronchostenosis
(Level of Evidence 4, Grade of Recommendation A).
• Echocardiography is always indicated in patients with carcin-
oid syndrome before surgery (Level of Evidence 4, Grade of
recommendation B, strong recommendation for good practice).
In PC, left- as well as right-side valves should be screened
(Level of Evidence 4, Grade of recommendation B).
surgery
Surgical removal is the treatment of choice for PCs. The aim is
to remove the tumor and to preserve as much lung tissue as pos-
sible. The surgical approach is dependent on the size, location,
and tissue type.
surgery for localized disease
complete anatomic resection and systematic nodal dissection.
For patients with peripheral lung tumors, the surgical extent of
choice is complete anatomic resection (lobectomy and
segmentectomy). The extent of lymph node management
should conform to the IASLC recommendations for the
certainty factor in the designation of R0 resection; this involves
a minimum of six nodes/stations, three of which should be
mediastinal including the subcarinal station [125].
In patients with limited pulmonary function, the practice of a
standard segment resection achieves better results than a broad
wedge resection. For peripheral AC, if only a limited sublobar
resection is carried out, there may be increased probability of
local recurrence postoperatively.
lung parenchymal-sparing surgery and systematic nodal
dissection. For patients with central airway tumors, lung
parenchymal-sparing surgery is the favored surgical objective.
This is in view of the low malignant and recurrence potential
(almost exclusively TC). Where possible, bronchial sleeve
resection (no lung tissue is removed) or a sleeve lobectomy
should be carried out in preference to pneumonectomy
(ideally with intraoperative frozen section of the resection
margins) [126]. If necessary, patients should be referred to
regional or national centers of excellence if such services are
not available locally. In the presence of distant pneumonitis
and destroyed lung parenchyma, an initial local endobronchial
resection to disobliterate the airway may be undertaken for
drainage before re-assessment for lung parenchymal-sparing
surgery [126].
Systemic nodal dissection should be carried out since lymph
node metastases may be present in up to 25% of cases in TC and
>50% in AC [96, 127].
local resection. Endobronchial (e.g. local diathermy resection
and laser resection) or peripheral (e.g. radiofrequency ablation,
RF) local ablation techniques may be employed with palliative
intent [126].
surgery for metastatic disease
There is little evidence to guide on surgery as part of multimod-
ality management of patients with metastatic disease. If pul-
monary surgery is considered, then consensus would be to
reserve surgery for patients with limited sites of disease with
‘curative intent’ where radical treatment is possible for all sites.
Such surgery is usually applied to TC and perhaps AC with low
mitotic counts.
liver resection
Surgical resection of liver metastases can be considered with
curative intent, to aid symptom control or for debulking when
>90% of tumor can be removed. Complete resection of liver me-
tastases has increased 5-year overall survival rates to over 70%
[128]. Thus, where possible, metastases should be resected. The
minimal requirements for curative intent are (i) resectable G1–
G2 liver disease with acceptable morbidity and <5% mortality;
(ii) absence of right heart insufﬁciency; (iii) absence of unresect-
able lymph node and extra-abdominal metastases; and (iv)
absence of diffuse or unresectable peritoneal carcinomatosis
[129].
surgery for recurrent disease
In general, recurrent disease is uncommon, and surgery may be
offered on the same premise of perioperative risk and stage se-
lection as primary surgery. Cases of regional recurrences have
been noted up to and beyond 30 years from the original resec-
tion of the primary tumor [130, 131]. Other studies have
reported recurrences >10 years from the initial resection [132–
134]. Sometimes, it is possible to treat local recurrences with
further surgery [134].
survey of surgical management
In June 2012, the European Society for Thoracic Surgery (ESTS,
http://www.ests.org/default.aspx) launched the Neuroendocrine
Tumors of the Lung Working Group (NETs-WG) and included
an electronic survey on PCs (E. Lim, personal communication).
The questionnaire included 19 questions, organized in four sec-
tions:
• Preoperative patient assessment.
• Surgical approach to particular clinical NET scenarios.
• Follow-up organization.
• Treatment of tumor recurrences/metastases.
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One hundred and seventy-two institutions worldwide replied to
this survey. Concerning the surgical approach to well-differentiated
lung NETs, an anatomic resection (either segmentectomy or
lobectomy) was suggested for a peripheral PC by more than
88% of responders, whereas only 19 (11%) considered a wedge
resection as an adequate surgical option. In total, 164 (95%)
responded that pneumonectomy should be avoided whenever
feasible in case of centrally located PC, performing parenchy-
mal-sparing resections, with preference for performing paren-
chymal-sparing resections; nevertheless, 8 (5%) still believed
that pneumonectomy was the treatment of choice. Lymphade-
nectomy, and in particular systematic hilar and mediastinal lym-
phadenectomy according to the ESTS recommendations for
intraoperative lymph node assessment [112], was suggested by
the majority of responders (64%); lymph node sampling was
considered adequate by 34% of institutions, while four centers
replied that they did not perform lymphadenectomy in any
patient with PC.
In the case of a ﬁt patient with resectable N2 PC, upfront
surgery was suggested by more than half of responders, while in-
duction chemotherapy was proposed by 71 centers (41%).
Furthermore, another unusual but sometimes described
[135–137] clinical scenario is represented by the multifocal PCs
(bilateral synchronous/metachronous ones). Currently, there is
no consensus concerning their treatment, and a therapeutic
strategy must be designed on a case-by-case basis. Looking at
the ESTS survey results, the lack of guidelines is conﬁrmed by
the fact that 36% of responders replied suggesting an anatomic
resection, but the other answers were split between a non-ana-
tomic resection and the resection of the larger lesion, only.
Finally, all but one of responders stated that surgery (if feas-
ible) should be proposed in the case of recurrent TC, whereas
other therapeutic options (biological therapy and conventional
chemotherapy) were also suggested in the case of recurrent AC.
local bronchoscopic therapy. PCs without an extraluminal
component can be treated at bronchoscopy resulting in an ex-
cellent long-term outcome with more tissue-sparing than im-
mediate surgical resection. For successful tumor eradication
with initial bronchoscopic treatment, the assessment of intra-
luminal versus extraluminal growth may be of much more im-
portance than histologic division between TC and AC [42]. To
decrease the risk of local recurrence, cryotherapy is a safe and
effective adjunct to endobronchial mechanical resection of TC
and tends not to be associated with long-term complications
such as bronchial stenosis [138]. In endoluminal PCs, laser
bronchoscopy may be a curative option and offers many
advantages as it is rapid, immediately effective and repeatable.
Laser bronchoscopy may also be used in association with
other therapies (i.e. radiotherapy) in cases of widespread intra-
mural inﬁltration with an extraluminal component [139]. If
the local treatment is not radical, surgical resection can follow
bronchoscopic treatment. This treatment strategy represents
a minimally invasive and parenchyma sparing alternative,
which may limit lobectomy to the cases of recurrence after
endobronchial treatment. Such local therapies need to be
considered in the context of patient medical status, type of PC,
and robust imaging including functional imaging to exclude
nodal spread.
surgery: recommendations for the best
practice
• In the case of localized disease, the surgical techniques of
choice are lobectomy or sleeve resection (Level of evidence 5,
Grade of recommendation A).
• Complete anatomic resection and systematic nodal dissection
are recommended as the resection extent of choice of patients
with peripheral tumors (Level of Evidence 5, Grade of recom-
mendation D).
• Lung parenchymal-sparing surgery should be preferred over
pneumonectomy (Level of Evidence 5, Grade of recommenda-
tion C).
• Local resection should be reserved for patients who are con-
sidered unacceptably high risk for bronchopulmonary surgery
(Level of Evidence 5, Grade of recommendation D).
• Endoluminal bronchoscopic therapy, more appropriately for
TC, should be reserved for patients who are considered
unacceptably high risk for bronchopulmonary surgery or
occasionally as a possible bridge to surgery (Level of Evidence
5, Grade of recommendation D).
• Resection of liver metastases should be carried out whenever
possible if curative intent is considered and in syndromic
patients when >90% of tumor burden can be removed. The
minimal requirements for curative intent include resectable TC
and low-grade AC; <5% mortality; absence of right heart insufﬁ-
ciency; absence of unresectable lymph node and extra-abdominal
metastases; and absence of unresectable peritoneal carcinoma-
tosis (Level of Evidence 4, Grade of recommendation C).
medical therapy
Advanced AC is more aggressive than TC [127, 140], and the
medical management must incorporate multidisciplinary
meeting review. The goals are to control both hormone-related
symptoms and tumor growth [79, 94, 141]. The prognostic het-
erogeneity and absence of curative therapeutic options at the
metastatic stage make quality of life a core issue. The key factors
to take into account for medical management are the spontan-
eous slope without treatment, the metastatic spread of the
primary tumor, SRS grade of uptake, and quality of control of
hormone-related symptoms. Based on the limited number of
studies available in patients with primary PC, these recommen-
dations also rely on data available for well-differentiated digest-
ive NETs. However, several signiﬁcant parameters that differ
from digestive NETs need to be stressed: a higher diversity of
hormone-related symptoms, a bronchial-speciﬁc carcinoid syn-
drome that may exist even in patients free of liver metastases,
low number of patients with distant metastases at diagnosis,
higher prevalence of bone, cutaneous and brain metastases, and
lower frequency of MEN1 syndrome.
control of hormonal secretion
Symptoms related to hormone secretion are present in up to
30% of advanced PCs. Carcinoid syndrome is the most frequent
functioning syndrome in PC. SSAs constitute the gold standard
for symptomatic control. A >50% improvement in the frequency
of ﬂushing symptoms and diarrhea has been reported after SSA
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in GEP NETs [142, 143]. A study speciﬁcally looking at the
management of carcinoid syndrome in seven patients with AC
showed complete control of symptoms with short-acting octreo-
tide injections [144]. The presence of carcinoid heart disease
should be carefully monitored.
Symptoms of Cushing syndrome are seen in 1–2% of patients
with a PC and may be the initial reason for seeking medical at-
tention. Cushing syndrome could be treated with commonly
available agents such as ketoconazole, metyrapone, etomidate,
or mifepristone. Ketoconazole, given at a daily dose of 600–800
mg, is the most popular and effective. Metyrapone is also often
used in this setting, and therapy starts at 1 g/day divided into
four doses and increased to a maximum dose of 4.5 g/day. For
ectopic GHRH secretion and acromegaly, SSAs can be of value.
Some patients with ectopic ACTH syndrome might respond
to SSA as well [79]. In the absence of hormonal control, other
antitumor options need to be considered and these include:
locoregional therapies [i.e. liver palliative surgery, transarterial
chemoembolization (TACE), and RF], combination of SSA with
interferon (IFN) and PRRT in selected patients [79, 95].
Prophylaxis against carcinoid crisis should be carried out before
surgical or locoregional interventions using an adequate dosage
of SSA. For major procedures, a preoperative intravenous bolus
of 100–200 µg, followed by a continuous infusion of 50 µg/h
during the procedure, is recommended and the dose can be
increased if required. The infusion should continue for 24 h
postoperatively before being slowly weaned over the next 48 h.
In such cases, it is likely that patients will require long-acting
SSA [79].
adjuvant tumor control
Currently, there is no consensus on adjuvant therapy in PCs
after complete resection. Indeed, both prognostic studies and
trials in the adjuvant setting are lacking. Only patients with AC
with positive lymph nodes, especially if there is a high prolifera-
tive index, should be considered for adjuvant therapy and dis-
cussed on an individual patient basis in the context of
multidisciplinary tumor board meeting. Clinical trials are
needed in this setting.
palliative tumor control
There are no prospective trials dedicated to PC that may guide
treatment, and most literature consists of case series or studies
that deal with a mixed population of primary NET patients.
Prognostic behavior and safety should be the ﬁrst parameter to
guide the therapeutic decision-making process.
In asymptomatic patients mainly with advanced TC or AC of
low proliferative index as well as low tumor burden, a watch and
see policy might be considered and explained to the patients
on the basis of regular cross-sectional imaging initially 3–6
monthly.
SSA can induce stabilization in 30–70% of patients with well-
differentiated NETs as demonstrated in multiple prospective
and retrospective studies that included PCs [145–147]. There
are no dedicated trials, available for lung primary. The rando-
mized placebo controlled PROMID study of octreotide LAR 30
mg versus placebo in midgut NET (n = 85) demonstrated antitu-
mor control with median time to progression signiﬁcantly
longer in the octreotide LAR 30 mg group than placebo, 14.3
months versus 6 months, respectively [148]. The phase III ran-
domized placebo controlled (CLARINET) study in 204 patients
with non-functional enteropancreatic NETs allocated to either
lanreotide Autogel (120 mg/28 days) or placebo, and showed
signiﬁcantly prolonged progression-free survival over placebo
(P = 0.0002) with 62% of lanreotide-treated patients versus 22%
of placebo treated having not progressed at 96 weeks [149].
The most commonly used long-acting SSAs are octreotide
LAR by deep i.m. injection and lanreotide Autogel given s.c.,
both administered every 28 days. Due to their excellent safety
proﬁle, SSA should be considered as ﬁrst-line systemic treatment
of patients with advanced PCs of low proliferation index and
positive SRS. Caution should be exercised in patients with high
tumor burden, high mitotic index or rapidly progressive tumor,
and a ﬁrst imaging carried out at 2–3 months.
In patients with slowly progressive tumors, multiple locore-
gional therapies aiming at reducing the tumor burden and tar-
geting the bronchial primary and liver, bone, or bronchial
metastases should be considered [79, 95]. In contrast with di-
gestive NETs, in whom mainly liver directed therapies are used,
extra-liver metastases are frequently found in case of PCs and
should also be considered as therapeutic targets. Surgical resec-
tion can be considered with intent of resection of macroscopic
metastases as outlined above mainly in slowly progressive TC
and low proliferative AC, or in case of symptoms related to the
primary location [129, 150, 151].
locoregional therapies
RF or cryoablation of the primary tumor are occasionally con-
sidered as an adjunct to surgery or whenever resection is not
possible. Liver but also bone or lung metastases constitute po-
tential targets of RF ablation. The size and anatomical locations
constitute major predictors of efﬁcacy. Liver metastases derive
the majority of their blood supply from the hepatic arteries;
therefore, selective embolization with either bland particles
(transarterial embolization, TAE) or cytotoxics such as doxo-
rubicin (TACE) are found to be effective in improving symp-
toms and radiological response, particularly in GEP NETs.
Radiological response rates between 33 and 73% have been
reported. There is no evidence suggesting a beneﬁcial response
of chemoembolization over particle embolization alone. There is
emerging evidence of using radioactive microspheres such as
Yttrium-90 in liver metastases. The added value of combination
of locoregional therapies as an adjunct to surgery or systemic
therapy in case of progressive disease should be kept in mind
[129, 150].
peptide receptor radiotargeted therapy
Well-differentiated PCs frequently express subtype 2 of the
SSTR family and this can be identiﬁed by Indium-111 SSA
scintigraphy or Gallium-68 SSA PET scans, which constitute
predictors of response. PRRT may be used to treat metastases of
TC and AC, with currently 90Yttrium-DOTA octreotide and
177Lutetium DOTA octreotide showing particular promise in
selected patients with high uptake at SRS. Prospective and ran-
domized trial results are warranted. Early phase II studies of
Yttrium-90 octreotide found the response rate to be as high as
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29% in seven PCs [152]. Although most studies are limited to
single centers, a large retrospective study looking at 1109 meta-
static NETs included 84 PCs, of which 28% showed a morpho-
logical response as estimated by RECIST criteria and 38.1%
showed a clinical response with a mean survival of 40 months.
Grade 3–4 toxicity is reported in 10–33% of patients, mainly
renal or hematological toxicities including irreversible renal tox-
icity (9.2%) [153]. Lutetium-177 DOTA octreotate (DOTATATE)
is a combination of the beta-emitting Lutetium coupled with
octreotate [154]. A study looking at foregut NETs with response
to Lutetium-177 included nine PCs, of which ﬁve showed a
partial response and just one had progressive disease [155]. The
number of bone metastases and baseline glomerular ﬁltration rate
correlated with toxicity.
systemic chemotherapy
Systemic chemotherapy should be considered in patients with
advanced unresectable progressive PC. In general, results with
chemotherapy have been largely disappointing and survival data
have to be interpreted with caution due to the small numbers of
patients, the mixed population of primary tumors, the absence
of progression before the study enrollment, and the old standard
criteria. Overall response rate (ORR) below 30% has been
described with 5-ﬂuorouracil (5-FU), dacarbazine, and temozo-
lomide (TMZ) alone or in combination, but also combinations
of 5-FU with streptozotocin (STZ) or oxalipatin [156–158].
Their value in the management of advanced PCs remains
unclear, but their level of G3-4 toxicity is expected above 10%.
TMZ is advocated as palliative treatment in PCs as it has been
the most widely studied in the subgroup of lung NET and has
an acceptable safety proﬁle. TMZ could also be considered in
case of brain metastases [159]. Analysis of methylguanine DNA
methyltransferase expression in NETs may help to select
responders [160]. In lung NETs, a STZ-based regimen showed
disappointing results with 7 of 7 patients progressing on STZ
and 5-FU [161]. In a randomized trial analyzing 5-FU–STZ
versus 5-FU–doxorubicin in symptomatic carcinoids including
22 PCs, 16% ORR was found with duration of 5 months and a
survival advantage of the FU–STZ combination, suggesting that
doxorubicin does not confer any beneﬁt in these patients [156].
A retrospective analysis of 5-FU–STZ and cisplatin included 79
patients with progressive NET; of which, 8 were PCs. The re-
sponse rate in this study for non-pancreatic primary sites was
25%, with overall median TTP 9.1 months. One PC patient had
a partial response enabling surgery and resection of primary and
nodal disease [162]. The combination of 5-FU and STZ plus or
minus cisplatin (FCist) was recently re-examined in a rando-
mized phase II trial of 85 consecutive NETs treated with this
regimen and no added value of cisplatin was found [163]. A
20% response rate to cisplatin or carboplatin was reported in
two studies speciﬁcally dedicated to well-differentiated PCs
[161, 164]. Due to its signiﬁcant rate of toxicity, cisplatin should
only be considered in patients with more aggressive, advanced
PCs.
mtor inhibitors
Everolimus may be a therapeutic option after failure of other
treatments in TC and AC. Mammalian target of Rapamycin
(mtor) has been identiﬁed as a kinase activated in the PI3K sig-
naling pathway of lung NETs [165]. Recently, mutations of
PI3CA were reported in TC and AC. The randomized phase III
RADIANT 2 trial assessed everolimus 10 mg + octreotide LAR
versus placebo + octreotide LAR in 429 patients in non-pancre-
atic functioning (carcinoid syndrome) NETs. The study demon-
strated a clinically signiﬁcant 5.1 month increase in median
progression-free survival [166]. Within this RADIANT 2 trial,
44 primaries were of bronchial origin [167]. The RAMSETE
study analyzed the antitumor beneﬁt of everolimus in 19
foregut-derived NETs with RECIST progression over a year. A
progression-free survival of 189 days was reported [168]. The
LUNA study is a three arm phase II trial assessing everolimus
alone versus pasireotide (a pan-SSTR analog) versus combin-
ation and started recruiting in 2013 (LUNA study, see www.
clinical trials.gov/ct2/show/NCT01563354). The randomized
phase III RADIANT 4 trial, which assessed everolimus 10 mg
versus placebo in 279 patients in non-functioning NETs includ-
ing lung PCs, has been closed for enrollment and the results are
expected in 2015.
antiangiogenesis agents
The place of antiangiogenic agents in PC remains uncertain.
Sunitinib is an orally administered kinase inhibitor small mol-
ecule with activity against a number of tyrosine kinase inhibitors
including VEGFR-1, -2, -3, platelet-derived growth factor recep-
tor (PDGFR)-a, and -b [169]. A phase II study evaluated the ac-
tivity of sunitinib in 109 NE patients including 41 with
carcinoids; of whom, 14 were foregut including PC. In the car-
cinoid patients, ORR was 2.4%, with stable disease in 83%, with
a TTP of 10.2 months and 1-year survival rate of 83.4 [170]. The
PAZONET study of pazopanib as a sequencing treatment in
progressive metastatic NET showed a clinical beneﬁt in 85% of
patients treated with pazopanib, including patients with lung
carcinoids [171]. Bevacizumab is an anti-vascular endothelial
growth factor (VEGF) monoclonal antibody and in a phase II
study patients were randomized to either bevacuzimab or pegy-
lated IFN, and 21 of 22 patients demonstrated a partial response
in the bevacizumab group where 4 patients were PCs [172]. One
phase II study analyzed the antitumor efﬁcacy of sorafenib plus
bevacizumab combination in 44 NETs, including 19 foregut
NETs. A 10% ORR was reported in digestive NETs [173]. More
studies looking at antiangiogenic activity in PC are required.
Promising results have been published with the combination of
bevacizumab and chemotherapy [174].
erlotinib and EGFR inhibitors
The epidermal growth factor (EGF) pathway has been found to
be expressed in PC, but no mutation has been reported to
date. In vitro and in vivo studies using the EGF receptor in-
hibitor erlotinib suggested a potential role and currently phase
II studies are ongoing (www.clinicaltrials.gov. NCT0084 3531
RAD001 and erlotinib in patients with NETs 2012; available
from: http://www.clinicaltrials.gov/ct2/results?termZNCT00843531).
Other pathways being investigated are ﬁbroblast growth factor and
MET pathways, with a range of new molecules being developed for
the VEGF and PDGF pathways [175].
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follow-up
After primary surgery, patients with TC and AC should be fol-
lowed initially at least yearly. However, the follow-up needs to
be long term even if less frequent to detect surgically manage-
able recurrences. Liver, mediastinum and abdomen lymph
nodes, lung, cutaneous, and/or bone metastases are routinely
evaluated by appropriate means. In case of high tumor burden
or speciﬁc symptoms, brain metastases should be considered.
Conventional imaging is carried out at 3 and 6 months and then
every 12 months in TC together with chromogranin A measure-
ments for the ﬁrst 2 years. Then annual chest X-ray and biochem-
istry proﬁle and a CT every 3 years long-term are recommended.
The frequency may be more frequent in R1 or node-positive
patients. SRS should be carried out at 12 months and then only
on suspicion of recurrence for TC. For AC, closer monitoring is
recommended. CT imaging should be carried out 3 months post-
surgery and then 6 monthly for 5 years with biochemical
markers. SRS imaging is carried out at 1 year and then on suspi-
cion of recurrence. After 5 years, annual CT should be carried
out. In selected patients with high proliferative index, FDG PET
may be more informative and replace SRS imaging.
At the time of a therapeutic intervention, patients should be
routinely monitored every 3 months. Fiberoptic bronchoscopy
is carried out for any symptoms suggestive of local progression
and on a routine basis every 5–10 years for TC or 1–3 years in
case of AC. The type of surgery, the R status, and the size of the
primary will also be taken into account to deﬁne the most ap-
propriate interval [79, 95, 176].
medical therapy: recommendations
for the best practice
• A watch and see policy may be considered in a subgroup of
asymptomatic patients mainly with TC or AC of low prolifera-
tive index (Level of Evidence 5; Grade of recommendation D).
• SSAs are the ﬁrst-line treatment of carcinoid syndrome and
acromegaly (Level of Evidence 3; Grade of recommendation B).
• In patients with Cushing syndrome, control of cortisol secretion
is needed (Level of Evidence 3; Grade of recommendation B).
• Bilateral adrenalectomy is a therapeutic option for refractory
Cushing syndrome (Level of Evidence 5; Grade of recommen-
dation D).
• SSA may be considered as ﬁrst-line systemic antiproliferative
treatment of patients with advanced unresectable PC of good
prognosis particularly TC and AC with low proliferative
index, and slowly progressive provided that SRI is positive
(Level of Evidence 3; Grade of recommendation B).
• Locoregional options including surgery (for primary and metas-
tases), TAE, and RF should always be considered for slow pro-
gressive PC (Level of Evidence 4; Grade of recommendation C).
• Cytotoxic treatment has been the standard for aggressive
metastatic PCs, although the available chemotherapy regi-
mens demonstrate a limited effect (Level of Evidence 3; Grade
of recommendation B).
• TMZ alone has demonstrated clinical beneﬁt (Level of
Evidence 3; Grade of recommendation C). A combination of
cisplatinum and etoposide is mainly used in high proliferating
PC (Level of Evidence 3; Grade of recommendation B).
• PRRT is an option in patients with tumors that demonstrate
strong expression of SSTRs (Level of Evidence 3; Grade of rec-
ommendation C, strong recommendation for good practice).
• There is evidence of preliminary efﬁcacy for everolimus in the
treatment of progressive PC. The ongoing randomized phase
III LUNA study will determine future management (Level of
Evidence 4; Grade of recommendation D).
• There is no consensus on adjuvant therapy in PCs after com-
plete resection. There might be consideration in patient with
AC of high proliferative index (Level of Evidence 4; Grade of
recommendation D).
• After primary surgery, patients with TC and AC should be
followed long term (Level of Evidence 4; Grade of recommen-
dation B).
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